CLINICAL TRIALS

Travere Therapeutics is committed to research and development of new therapies for rare diseases.

We are currently enrolling patients in the following clinical studies:

 

The REPLACE Registry

REPLACE Registry

Investigational therapy: Cholic acid
Therapeutic area: BASD; PBD-ZSD with liver involvement
Study type: Observational
Learn more: NCT03115086

 

ACAPELLA study logo

ACAPPELLA Study

Natural History Study of Homocystinuria Caused by Cystathionine Beta-synthase Deficiency

Therapeutic area: HCU
Study type: Observational
Learn more: hcuconnection.com | NCT03406611

 

EPPIK logo

EPPIK Study

Sparsentan Treatment in Pediatrics with Proteinuric Glomerular Diseases (EPPIK)

Therapeutic area: FSGS; IgAN
Study type: Phase 2
Learn more: eppikclinicalstudy.com | NCT05003986

RESTORE

RESTORE Study

Investigational therapy: Chenodeoxycholic acid
Therapeutic area: CTX
Study type: Phase 3
Learn more: CTXrestore.com | NCT04270682

 

Compose

COMPOSE Study

Investigational therapy: Pegtibatinase (TVT-058)
Therapeutic area: HCU
Study type: Phase 1/2
Learn more: hcuconnection.com | NCT03406611

 

HONUS Study

Humanistic Burden of FSGS and IgAN

Therapeutic area: FSGS; IgAN
Study type: Observational
Learn more: NCT05200871

Active clinical studies with completed enrollment:

duplex

DUPLEX Study

Investigational therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 3
Learn more: NCT03493685

 

PROTECT IgAN

PROTECT Study

Investigational therapy: Sparsentan
Therapeutic area: IgAN
Study type: Phase 3
Learn more: NCT03762850

duet

DUET Study

Investigational Therapy: Sparsentan
Therapeutic area: FSGS
Study type: Phase 2
Learn more: NCT01613118